For the first time in Aragon, the Clinic incorporates a new implant to treat glaucoma
1 July 2020
Developed a mask that self-disinfects with heat
2 July 2020
An independent investigation, not yet published, by several workers at the Barbastro hospital (Huesca) has circulated on social networks and linked flu vaccination with COVID-19.
The Spanish Association of Vaccinology (AEV) has denied a study that links a component of the flu vaccine, polysorbate 80, and coronavirus infection with what it considers that the authors of the work "contravene" the principles of epidemiology and the research methodology.
It specifically refers to an independent investigation, not yet published, by several workers at the Barbastro hospital (Huesca) that has circulated on social networks and that links flu vaccination with COVID-19. In a statement, the AEV "categorically" rejects this study and exposes a series of clinical, epidemiological and methodological considerations that "completely invalidate" the hypothesis of its authors.
In this way, he maintains that in all countries deaths from coronavirus have been concentrated in the oldest ages, in which there are great variations in terms of flu vaccine coverage, ranging from 5% in China to more than 70% in the UK. In addition, there has been "a significant" number of people under 65 years of age affected when this vaccine is not administered to them.
The AEV experts emphasize that Polysorbate 80, one of the components of the vaccine cited by the authors of the Barbastro study, is also present in others in the children's calendar, and children have precisely been the least affected by the coronavirus. .
According to the AEV, the authors of the study postulate that among the deceased, vaccination coverage was higher than in the Barbastro Health Sector, but they do not take into account that the outbreaks and deaths have affected people living in residences to a greater extent. and that it is in those places where flu vaccination rates are highest.
The AEV assures that the authors of the study acknowledge that they considered the possibility of contamination of influenza vaccines with SARS-CoV-2, analyzing a vaccine to look for possible contamination. On this point, the AEV statement indicates that the vaccines administered in the 2019-20 campaign are manufactured, packaged and distributed between March and October 2019.
Thus, it states that possible contamination with the SARS-CoV-2 virus would go "against both the credibility of the quality processes carried out in all vaccines and the time of the appearance of the virus." In addition, among other things, it continues, the majority of the population was vaccinated between October and December 2019 and the cases occurred between March and this year.
